Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Buprenorphine-naloxone maintenance following release from jail.

Lee JD, Grossman E, Truncali A, Rotrosen J, Rosenblum A, Magura S, Gourevitch MN.

Subst Abus. 2012;33(1):40-7. doi: 10.1080/08897077.2011.620475.

2.

Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.

Gunderson EW, Wang XQ, Fiellin DA, Bryan B, Levin FR.

Addict Behav. 2010 May;35(5):537-40. doi: 10.1016/j.addbeh.2010.01.001. Epub 2010 Jan 18.

3.

Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.

Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S.

Ann Fam Med. 2007 Mar-Apr;5(2):146-50.

4.

Is buprenorphine-naloxone ready for prime time in the treatment of opioid addiction in managed care?

Curtiss FR.

J Manag Care Pharm. 2008 Mar;14(2):195-7. No abstract available.

5.

Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone.

Barry DT, Savant JD, Beitel M, Cutter CJ, Moore BA, Schottenfeld RS, Fiellin DA.

J Addict Med. 2012 Dec;6(4):274-9. doi: 10.1097/ADM.0b013e31826d1df3.

6.

Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.

Ziedonis DM, Amass L, Steinberg M, Woody G, Krejci J, Annon JJ, Cohen AJ, Waite-O'Brien N, Stine SM, McCarty D, Reid MS, Brown LS Jr, Maslansky R, Winhusen T, Babcock D, Brigham G, Muir J, Orr D, Buchan BJ, Horton T, Ling W.

Drug Alcohol Depend. 2009 Jan 1;99(1-3):28-36. doi: 10.1016/j.drugalcdep.2008.06.016. Epub 2008 Sep 20.

7.

Buprenorphine treatment in an urban community health center: what to expect.

Cunningham C, Giovanniello A, Sacajiu G, Whitley S, Mund P, Beil R, Sohler N.

Fam Med. 2008 Jul-Aug;40(7):500-6.

8.

In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.

[No authors listed]

Med Lett Drugs Ther. 2013 Oct 14;55(1427):83. No abstract available.

PMID:
24129113
9.

Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care.

Apelt SM, Scherbaum N, Gölz J, Backmund M, Soyka M.

Pharmacopsychiatry. 2013 May;46(3):94-107. doi: 10.1055/s-0032-1330033. Epub 2013 Jan 4.

PMID:
23293011
10.

Tramadol dependence: treatment with buprenorphine/naloxone.

Ritvo JI, Koonce R, Thurstone CC, Causey HL 3rd.

Am J Addict. 2007 Jan-Feb;16(1):67-8. No abstract available.

PMID:
17364425
11.

Pain and associated substance use among opioid dependent individuals seeking office-based treatment with buprenorphine-naloxone: a needs assessment study.

Barry DT, Savant JD, Beitel M, Cutter CJ, Moore BA, Schottenfeld RS, Fiellin DA.

Am J Addict. 2013 May-Jun;22(3):212-7. doi: 10.1111/j.1521-0391.2012.00327.x.

12.

Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.

Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, Samet JH.

Arch Intern Med. 2011 Mar 14;171(5):425-31. doi: 10.1001/archinternmed.2010.541.

13.

A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.

Matson SC, Hobson G, Abdel-Rasoul M, Bonny AE.

J Addict Med. 2014 May-Jun;8(3):176-82. doi: 10.1097/ADM.0000000000000035.

PMID:
24695018
14.

Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.

D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, Bernstein SL, Fiellin DA.

JAMA. 2015 Apr 28;313(16):1636-44. doi: 10.1001/jama.2015.3474.

15.

Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?

Srivastava A, Kahan M, Nader M.

Can Fam Physician. 2017 Mar;63(3):200-205. Review.

17.

Use and misuse of opioid replacement therapies: a Queensland study.

Smirnov A, Kemp R.

Subst Use Misuse. 2012 Jan;47(1):78-85. doi: 10.3109/10826084.2011.629017.

PMID:
22216993
18.

Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.

Mokri A, Chawarski MC, Taherinakhost H, Schottenfeld RS.

Addiction. 2016 May;111(5):874-82. doi: 10.1111/add.13259. Epub 2016 Jan 26.

PMID:
26639678
19.

Management of opioid painkiller dependence in primary care: ongoing recovery with buprenorphine/naloxone.

Hard B.

BMJ Case Rep. 2014 Nov 28;2014. pii: bcr2014207308. doi: 10.1136/bcr-2014-207308. Review.

20.

A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.

Amass L, Pukeleviciene V, Subata E, Almeida AR, Pieri MC, D'Egidio P, Stankova Z, Costa A, Smyth BP, Sakoman S, Wei Y, Strang J.

Addiction. 2012 Jan;107(1):142-51. doi: 10.1111/j.1360-0443.2011.03577.x. Epub 2011 Oct 12.

PMID:
21749526

Supplemental Content

Support Center